Compare Enovix Corporation (ENVX) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Illumina, Inc. — how do they compare? Enovix Corporation trades at $4.59 (market cap $1.11B), while Illumina, Inc. trades at $189.66 (market cap $28.32B). The key difference: Illumina, Inc. is far larger — about 25.5× Enovix Corporation's market cap, and Illumina, Inc. is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| ENVX | ILMN | |
|---|---|---|
Market Cap | $1.11B | $28.32B |
Sector | Technology | Health |
52-Week High | $15.93 | $194.33 |
52-Week Low | $4.84 | $91.00 |
Enterprise Value | $1.13B | $29.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX is trading at $4.59, down 9.29% in the last session, with a bearish technical signal. The company shows consistent quarterly earnings beats but remains deeply unprofitable with a -499.64% net income margin. Recent positive developments include the appointment of a former Apple operations leader as COO and progress in commercial battery production for smart eyewear and smartphone markets.
Despite analyst optimism (75% buy ratings, $12.75 consensus target), ENVX faces significant execution risks as it scales production. The stock offers speculative growth potential in advanced battery technology but requires substantial revenue acceleration to justify current valuations amid persistent cash burn and negative profitability.
Illumina (ILMN) trades at $188.27, down 1.53% on the day, yet maintains a strong technical and fundamental posture. The stock is in a bullish trend, supported by consistent earnings beats, robust profitability margins, and positive analyst sentiment. Recent news highlights strong momentum in 2026, driven by sequencing demand and new product launches, positioning the company for growth despite competitive pressures.
The outlook for ILMN is positive, with earnings growth and market leadership in genomics offering upside potential. Key risks include intensifying competition from new entrants like Roche and execution challenges in a dynamic healthcare landscape. Investor sentiment remains buoyant, but vigilance on competitive threats and margin sustainability is warranted for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
